Viewing data from:

TOBRAMYCIN SULFATE

ANDA

TOBRAMYCIN SULFATE | A064021 | APOTHECON INC DIV BRISTOL MYERS SQUIBB

2 strengths0 unique patents0 unique exclusivities

Medicare Part B Spending

CMS physician-administered drug spending for Tobramycin Sulfate (2023)

Total Spending

$55K

Total Claims

13,948

Beneficiaries

8,457

ASP Price

—

HCPCS: J3260 — Injection, tobramycin sulfate, up to 80 mg

Source: CMS Medicare Part B Spending by Drug (2023). Shows physician-administered drug costs.

API Supply Chain1 active DMF2 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTDTOBRAMYCIN SULFATE

DMF 278412013

LILLY RESEARCH LABORATORIESInactiveTOBRAMYCIN SULFATE

DMF 135131998

FUJIAN FUKANG PHARMACEUTICAL CO LTDInactiveTOBRAMYCIN SULFATE

DMF 171092004

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 10MG BASE/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: May 31, 1994

No patent or exclusivity listings for this strength.

#002 — EQ 40MG BASE/ML

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: May 31, 1994